LK8 peptide

consists of KIV9, KIV10, and KV; induces apoptosis of endothelial cells

Also Known As:

apolipoprotein(a) kringle V; rhLK8 peptide

Networked: 8 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Lipids: 114793
- Lipoproteins: 18361
  - Apolipoproteins: 14925
    - Apolipoproteins A: 1020
      - LK8 peptide: 8
Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Lipoproteins: 18361
    - Apolipoproteins: 14925
      - Apolipoproteins A: 1020
        LK8 peptide: 8
  - Apoproteins: 638
    - Apolipoproteins: 14925
      - Apolipoproteins A: 1020
        LK8 peptide: 8
- Peptides: 82426
  - Peptide Fragments: 373
    - LK8 peptide: 8

Experts

1.	Kim, Jang-Seong: 5 articles (06/2014 - 04/2012)
2.	Lee, Ho-Jeong: 5 articles (06/2014 - 04/2012)
3.	Yoon, Yeup: 5 articles (06/2014 - 04/2012)
4.	Yu, Hyun-Kyung: 5 articles (06/2014 - 04/2012)
5.	Kim, Sun Jin: 4 articles (06/2014 - 04/2012)
6.	Ahn, Jin-Hyung: 4 articles (01/2014 - 06/2012)
7.	Yi, Lee S H: 2 articles (06/2014 - 06/2013)
8.	Park, Yong-Keun: 2 articles (08/2012 - 04/2012)
9.	Ahn, Joong Bae: 1 article (12/2017)
10.	Chung, Hyun Cheol: 1 article (12/2017)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 04/01/2012 - "We determined whether recombinant human apolipoprotein(a) kringle V, rhLK8, produces therapeutic efficacy in an orthotopic human prostate cancer animal model. " 04/01/2012 - "Targeted antivascular therapy with the apolipoprotein(a) kringle V, rhLK8, inhibits the growth and metastasis of human prostate cancer in an orthotopic nude mouse model."
2.	Neoplasms (Cancer) 12/01/2017 - "A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors." 06/01/2013 - "Human apolipoprotein(a) kringle V (rhLK8) is an angiogenesis inhibitor and is currently under development as an anti-cancer therapeutic. " 01/01/2014 - "Suppression of colorectal cancer liver metastasis by apolipoprotein(a) kringle V in a nude mouse model through the induction of apoptosis in tumor-associated endothelial cells."
3.	Retinal Neovascularization 06/01/2012 - "In this study, we demonstrated the inhibitory effect of recombinant human apolipoprotein(a) kringle V (rhLK8) in an animal model of ischemia-induced retinal neovascularization. " 06/01/2012 - "Human apolipoprotein(a) kringle V inhibits ischemia-induced retinal neovascularization via suppression of fibronectin-mediated angiogenesis."
4.	Ischemia 06/01/2012 - "In this study, we demonstrated the inhibitory effect of recombinant human apolipoprotein(a) kringle V (rhLK8) in an animal model of ischemia-induced retinal neovascularization. " 06/01/2012 - "Human apolipoprotein(a) kringle V inhibits ischemia-induced retinal neovascularization via suppression of fibronectin-mediated angiogenesis."
5.	Carcinoma (Carcinomatosis) 06/01/2014 - "The present study compared the effect of combination therapy using human apolipoprotein(a) kringle V (rhLK8) to conventional chemotherapy with paclitaxel for human ovarian carcinoma producing high or low levels of vascular endothelial growth factor (VEGF). "

Related Drugs and Biologics

1.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
2.	Paclitaxel (Taxol)
3.	Angiogenesis Inhibitors
4.	Peptides (Polypeptides)
5.	Fibronectins (Fibronectin)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Intravenous Infusions